scholarly journals Building a Knowledge Graph Representing Causal Associations Between Risk Factors and Incidence of Breast Cancer

2021 ◽  
Author(s):  
Ali Daowd ◽  
Michael Barrett ◽  
Samina Abidi ◽  
Syed Sibte Raza Abidi
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Chronic Disease ◽  
Information Seeking ◽  
Relevant Literature ◽  
Knowledge Graph ◽  
Evidence Based ◽  
Biomedical Knowledge ◽  
Semantic Associations ◽  
Literature Based Discovery

This paper explores the use of semantic- and evidence-based biomedical knowledge to build the RiskExplorer knowledge graph that outlines causal associations between risk factors and chronic disease or cancers. The intent of this work is to offer an interactive knowledge synthesis platform to empower health-information-seeking individuals to learn about and mitigate modifiable risk factors. Our approach analyzes biomedical text (from PubMed abstracts), Semantic Medline database, evidence-based semantic associations, literature-based discovery, and graph database to discover associations between risk factors and breast cancer. Our methodological framework involves (a) identifying relevant literature on specified chronic diseases or cancers, (b) extracting semantic associations via knowledge mining tool, (c) building rich semantic graph by transforming semantic associations to nodes and edges, (d) applying frequency-based methods and using semantic edge properties to traverse the graph and identify meaningful multi-node NCD risk paths. Generated multi-node risk paths consist of a source node (representing the source risk factor), one or more intermediate nodes (representing biomedical phenotypes), a target node (representing a chronic disease or cancer), and edges between nodes representing meaningful semantic associations. The results demonstrate that our methodology is capable of generating biomedically valid knowledge related to causal risk and protective factors related to breast cancer.

How oncologists adhere to evidence-based G-CSF-guidelines to prevent febrile neutropenia: A sample survey in hospitals and practices in Germany.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6591-6591 ◽  
Author(s):  
Hartmut Link ◽  
Josef Nietsch ◽  
Markus Kerkmann ◽  
Petra Angelika Ortner ◽  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Lung Cancer ◽  
Febrile Neutropenia ◽  
Sample Size ◽  
Malignant Lymphoma ◽  
Sample Survey ◽  
Evidence Based ◽  
Intermediate Risk ◽  
Evidence Based Guidelines

6591 Background: Primary G-CSF prophylaxis after chemotherapy is recommended in evidence based guidelines (GL), if the risk of febrile neutropenia (FN) is high (≥20%), or intermediate (≥ 10% - 20%) in case of risk factors. The aim was to evaluate, if G-CSF is used as proposed by GL, to identify determinants of GL implementation and adherence. Methods: The sample size was calculated at 2% of the incidence of malignant lymphoma, breast and lung cancer in Germany. Pts who had received 3-9 cycles of chemotherapy with a FN risk ≥10% between 5/2011 to 4/2012 were documented retrospectively. Results: 286 lymphoma, 666 lung cancer and 976 breast cancer pts were collected from 87 hospitals and 59 oncology practices with 195 physicians participating. Adherence to GL was higher in physicians up to 10 than over 10 years of experience. Conclusions: The adherence to and acceptance of GL for G-CSF may not be sufficient. Patient risk factors are underestimated therefore resulting in a possible underuse of G-CSF. Physicians may underestimate FN risk in pts who have an intermediate risk of FN and they overestimate their adherence to the GL. [Table: see text]

scholarly journals Metastatic Breast Cancer as a Chronic Disease: Evidence-Based Data on a Theoretical Concept

Breast Care ◽  
2019 ◽  
Vol 15 (3) ◽  
pp. 281-288
Author(s):  
Constanze Elfgen ◽  
Giacomo Montagna ◽  
Seraina Margaretha Schmid ◽  
Walter Bierbauer ◽  
Uwe Güth
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Chronic Disease ◽  
Progressive Disease ◽  
Case Fatality ◽  
Metastatic Breast ◽  
Theoretical Concept ◽  
First Year ◽  
Evidence Based ◽  
Entire Cohort

Background: We challenge the concept of metastatic breast cancer (MBC) as a chronic disease. Methods: We analyzed an unselected cohort of 367 patients who were diagnosed with MBC over a 22-year period (1990–2011). Results: In order to create a “chronic disease subgroup”, we separated those patients from the entire cohort in whom systemic therapy was not applied after the diagnosis of MBC (n = 53; 14.4%). Three hundred fourteen patients (85.6%) comprised the “chronic disease subgroup”. The vast majority of those patients (89.8%) died of progressive disease after a median metastatic disease survival (MDS) of 25 months. Twenty patients (6.4%) died of non-MBC-related causes (MDS 38.5 months). Approximately 1 in 4 patients (26.8%) died within the first year after the MBC diagnosis. The 3- and 5-year MDS rates were 35.4 and 16.2%, respectively. Only 12 patients (3.8%) were exceptional survivors (MDS >10 years). Conclusion: The term “chronic disease” might be appropriate in selected MBC cases, bringing MBC into alignment with “classical” chronic diseases such as diabetes and hypertension. However, most cases display fundamental differences with regard to temporal progression and above all the case fatality rate. More than 90% of patients in the “chronic disease subgroup” died of the disease with a MDS of 2–3 years (even those who underwent systemic palliative therapies). Doctors and patients might understand the term “chronic disease” differently. The term must be used sparingly and explained carefully in order to create a common level of communication based on a shared understanding which avoids awakening false hopes and fostering misleading expectations.

scholarly journals Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer— a patient survey

2018 ◽  
Vol 25 (4) ◽  
Author(s):  
N. LeVasseur ◽  
C. Stober ◽  
M. Ibrahim ◽  
S. Gertler ◽  
J. Hilton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Vascular Access ◽  
Systemic Therapy ◽  
Perceived Risk ◽  
Early Stage ◽  
Patient Survey ◽  
Early Stage Breast Cancer ◽  
Evidence Based ◽  
Central Catheter

Background The choice of vascular access for systemic therapy administration in breast cancer remains an area of clinical equipoise, and patient preference is not consistently acknowledged. Using a patient survey, we evaluated the patient experience with vascular access during treatment for early-stage breast cancer and explored perceived risk factors for lymphedema.Methods Patients who had received systemic therapy for early-stage breast cancer were surveyed at 2 Canadian cancer centres.Results Responses were received from 187 patients (94%). The route of vascular access was peripheral intravenous line (IV) in 24%, a peripherally inserted central catheter (picc) in 42%, and a surgically inserted central catheter (port) in 34%. Anthracycline-based regimens were associated with a greater use of central vascular access devices (cvads— that is, a picc or port; 86/97, 89%). Trastuzumab use was associated with greater use of ports (49/64, 77%). Although few patients (7%) reported being involved in the decisions about vascular access, most were satisfied or very satisfied (88%) with their access type. Patient preference centred mainly on avoiding delays in the initiation of chemotherapy. Self-reported rates of complications (183 evaluable responses) were infiltration with peripheral IVs (9/44, 20%), local skin infections with piccs (7/77, 9%), and thrombosis with ports (4/62, 6%). Perceived risk factors for lymphedema included use of the surgical arm for blood draws (117/156, 75%) and blood pressure measurement (115/156, 74%).Conclusions Most patients reported being satisfied with the vascular access used for their treatment. Improved education and understanding about the evidence-based requirements for vascular access are needed. Perceived risk factors for lymphedema remain variable and are not evidence-based.

The Preschool Stuttering Screen for Health Care Professionals

2011 ◽  
Vol 21 (2) ◽  
pp. 59-62
Author(s):  
Joseph Donaher ◽  
Christina Deery ◽  
Sarah Vogel
Keyword(s):  
Risk Factors ◽  
Health Care ◽  
Differential Diagnosis ◽  
Preschool Children ◽  
Health Care Professionals ◽  
Healthcare Professionals ◽  
Evidence Based ◽  
Developmental Profile

Healthcare professionals require a thorough understanding of stuttering since they frequently play an important role in the identification and differential diagnosis of stuttering for preschool children. This paper introduces The Preschool Stuttering Screen for Healthcare Professionals (PSSHP) which highlights risk factors identified in the literature as being associated with persistent stuttering. By integrating the results of the checklist with a child’s developmental profile, healthcare professionals can make better-informed, evidence-based decisions for their patients.

Physician Advice to Reduce Chronic Disease Risk Factors

1994 ◽  
Vol 10 (6) ◽  
pp. 367-371 ◽  
Author(s):  
Carol Friedman ◽  
Ross C. Brownson ◽  
Dan E. Peterson ◽  
Joan C. Wilkerson
Keyword(s):  
Risk Factors ◽  
Chronic Disease ◽  
Disease Risk ◽  
Chronic Disease Risk ◽  
Physician Advice

Incidence and Risk Factors of the Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab

2018 ◽  
Vol 35 (2) ◽  
pp. 177-183
Author(s):  
정지혜 ◽  
여미진 ◽  
박애령 ◽  
황보신이 ◽  
나현오 ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Breast Cancer Patients

Cancer screening. Current state of the problem

2020 ◽  
pp. 4-12
Author(s):  
Marina Kochiyeva
Keyword(s):  
Breast Cancer ◽  
Cervical Cancer ◽  
Colon Cancer ◽  
Cancer Screening ◽  
Target Population ◽  
Evidence Based ◽  
Screening Programs ◽  
Current State ◽  
Methodological Approaches ◽  
Based Medicine

Data on modern methodological approaches that are used in screening for cancer are summarized. General principles of organizing screening studies are examined from the perspective of evidence-based medicine, target population, research methods, and effectiveness of the implemented screening programs for breast cancer, cervical cancer, and colon cancer are determined.

Sign in / Sign up

Export Citation Format

Share Document